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Background: To describe the rates, indications, and adverse effects of psychotropic drug prescription in a specialist
tertiary hospital child and adolescent eating disorder service.
Methods: Retrospective case note study of all active eating disorder patients (N = 115) over the period of treatment
from referral to time of study (M = 2 years), covering patient demographics, clinical characteristics, drug
prescriptions, indications, and adverse effects.
Results: Psychotropic drugs were prescribed in 45% of cases, most commonly antidepressants (41%), followed by
anxiolytics (29%) and antipsychotics (22%), with 8% initiated before referral to the specialist eating disorder
program. Common indications were depressed mood, agitation, anxiety, and insomnia. Patient clinical severity and
complexity was associated with prescribing. Adverse effects, mostly minor, were recorded in 23% of antidepressant
prescriptions, 39% of antipsychotic prescriptions, and 13% of anxiolytic prescriptions. Second generation
antipsychotic prescription was associated with subsequent new onset binge eating, in this preliminary observational
study. Self-harm by overdose of psychotropics occurred in 11% of patients prescribed medication.
Conclusions: Psychotropic medications were frequently prescribed to adolescent eating disorder patients to treat
distressing symptoms. Prospective randomised controlled trials to clarify efficacy and safety are needed. Given the
difficulties of conducting clinical trials in this population, services are encouraged to monitor and audit medication
safety and efficacy in everyday practice, and to report their findings.
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Eating disorders (EDs) affect up to 15% of women in their
lifetime [1] and have their peak incidence in adolescence
[2]. The nutritional compromise, particularly in anorexia
nervosa (AN), occurs during critical brain development
and is associated with brain mass reduction [3] and neuro-
psychological abnormalities [4]. Adolescent EDs are asso-
ciated with a mortality of approximately 2.9% over 6 years
[5] and profound negative impacts on physical, psycho-
logical, and social development [2].
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reproduction in any medium, provided the orspecialist multidisciplinary team approach with medical,
nutritional, social, and psychological care, including family
and/or individual psychotherapy [6-8]. Family-based treat-
ment, a specific treatment modality that directly addresses
the ED, has a moderate level of evidence in paediatric AN
[2]. There is limited evidence to guide treatment selec-
tion among paediatric bulimia nervosa (BN) or EDs not
otherwise specified (EDNOS) [6,8]. Medication is not
recommended as the sole treatment for any ED [6-9].
Nonetheless, psychotropic drugs are prescribed, often
off-label, for comorbidities, distress, agitation, and
sometimes in an attempt to treat core ED symptoms.
Impact on growth and development is largely un-
known, and there is little evidence to guide dosage [10].
Selective serotonin reuptake inhibitors (SSRIs) such as
fluoxetine have been prescribed to adolescents with EDsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disorder (OCD). In young people without EDs, there is
high-quality evidence supporting efficacy of fluoxetine and
some other SSRIs for these disorders [11]. However, there
is no evidence to support treatment with SSRIs in patients
with a low body mass index; the available case reports and
studies suggest that SSRIs are ineffective for symptoms of
depression, anxiety, or OCD in very underweight patients,
which is pertinent to AN [10]. There was no benefit from
SSRIs in relapse prevention, core ED symptoms, depressive
or obsessive-compulsive symptoms in a retrospective study
of partially weight-restored female adolescents with AN
[12]. Likewise, fluoxetine did not prevent relapse in
weight-restored AN adults receiving cognitive-behavioural
therapy [13]. The well-publicised finding of a small but
significant increased risk of suicidality in youth after com-
mencement of SSRIs was derived from meta-analyses of
trials conducted for depression and anxiety disorders [14];
it is unknown to what extent these findings generalise to
EDs. Individuals with EDs have an elevated risk of
suicidality and deliberate self-harm [15,16]. Drug overdose
is a leading method of suicide particularly among females
[17], yet little is known about risk of overdose of prescrip-
tion drugs in this context.
Second generation antipsychotics (SGAs) such as olan-
zapine are used as an adjunctive treatment for EDs, for
anxiety, agitation, and ruminations on themes of food and
body image, and to attempt to promote weight gain in
malnourished patients. There has recently been interest in
olanzapine treatment for AN, accompanied by increasing
caution about potential adverse effects. Studies in adults
with AN are mixed, though some trials suggest that SGAs
improve core symptoms [18]. Prescribing pharmacother-
apy involves weighing up potential benefits and risks.
Norris et al. [19] published a retrospective matched-groups
comparison of 86 female adolescents with AN, 43 treated
with olanzapine, and 43 matched comparators. No conclu-
sions could be drawn regarding efficacy. The most notable
finding was of adverse effects in 56% of patients treated
with olanzapine, most commonly sedation (40%) and lipid
abnormality (29% of those screened), highlighting the need
to maintain surveillance of medication safety – most older
studies do not report lipid or blood glucose monitoring.
Olanzapine, quetiapine, and risperidone can cause weight
gain and metabolic adverse effects, such as impaired glu-
cose tolerance and dyslipidaemia in children and adoles-
cents, to a greater extent than in adults [20]. They may
have a negative effect on bone density, mediated by
hyperprolactinaemia [21]. There is also a potential for car-
diac side-effects such as QTc prolongation associated with
SGA usage. The QTc interval has been shown to be longer
in AN than in healthy controls, suggesting particular vul-
nerability [22]. There is a case report of QTc prolongation
occurring repeatedly in an adolescent with AN treated witholanzapine, then risperidone, in combination with fluoxet-
ine [23]. The cardiac risk is of particular concern for pa-
tients with AN due to nutritional deficiencies, impaired
calcium and phosphate metabolism, and hypokalaemia in
patients with symptoms of purging, which predispose to
life-threatening arrhythmias. Hypokalaemia can cause U
wave formation and flattened T waves on the ECG, which
complicates the measurement of the QTc interval, and so
the QTc interval needs to be interpreted carefully in such
cases [24].
SGAs are known to increase appetite and cause weight
gain, and some case reports and series, including one on a
child with AN, have linked SGAs to emergence, exacerba-
tion, and recurrence of binge eating [25-30]. McKnight
and Park [31] found no published evidence that SGAs
contribute to the development of binge eating, but
reported their clinical observation that SGAs appear to ex-
acerbate binge eating in patients with pre-existing bulimic
symptoms. In a consecutive case series of 74 adolescent
and adult psychiatric patients treated with clozapine or
olanzapine, emergent binge-eating symptomatology or
full-blown EDs were more common among those with a
history of EDs than those without [29]. Emergent binge
eating in patients with restricting AN is a common event:
more than half of a sample of young adult women with
restricting AN crossed over to the binge eating/purging
subtype or to BN in a 7 year longitudinal study [32]. Given
these findings, case reports and clinical impressions are
difficult to interpret. Dysregulation of eating behaviours
through either restricting or binge eating is distressing and
problematic, so it is important to be vigilant regarding
binge eating as a potential adverse effect of medication.
Anxiolytic drugs such as benzodiazepines are pre-
scribed to patients with EDs to control insomnia, agita-
tion, and anxiety and to facilitate nutritional resuscitation,
but there are currently no randomized controlled trials
and little literature of any kind describing their use [18]. In
children with anxiety disorders, problems with disinhib-
ition, irritability, and drowsiness have been reported
with clonazepam [33]. In adults with anxiety disorders,
benzodiazepines may impair memory and learning and
in some instances reduce the efficacy of specific psycho-
therapies [34].
A recent report of psychotropic medication use in
American adult women with anorexia nervosa between
1997 and 2009 found that of 539 patients presenting
for bone density screening, 53% were currently taking
a psychotropic medication, most commonly antide-
pressants (48%) and antipsychotics (13%) [21]. The use
of atypical antipsychotics (most commonly quetiapine)
had doubled over the 13 year period of the study.
Widespread use of these medications is of concern,
given the absence of conclusive evidence of benefit and
the potential adverse effects.
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specialist child and adolescent ED services. In a retrospect-
ive case note study of 60 children and adolescents with AN
newly referred to an Italian specialist psychiatric unit be-
tween 2000 and 2004, 16 (32%) were prescribed psycho-
tropic medication [35]. Seventy-six percent of prescriptions
were for antidepressants, most commonly paroxetine and
sertraline, prescribed for comorbid depression or OCD.
Antipsychotic medications accounted for 21% of prescrip-
tions, most commonly haloperidol and olanzapine, for
indications of “anguish” and “thought disorders”. Sixteen
percent received two or more medications concurrently.
Adverse events were reported for 29% of prescriptions. In
a retrospective case note study of 308 ED cases seen in
seven specialist UK child and adolescent ED services dur-
ing 2005 to 2006 [36], psychotropic drugs were prescribed
for 27% of patients, mainly those with AN. Fluoxetine and
olanzapine were the most common prescriptions, and the
most common indications were depression, anxiety and
“pseudo-psychotic” concerns about weight. Adverse effects
were reported for 15% of antidepressant prescriptions and
28% of antipsychotic prescriptions, but 38% of olanzapine
prescriptions. No conclusions could be drawn about the ef-
fectiveness of medications.
Clinicians treating children and adolescents with EDs
currently lack evidence-based guidance about psycho-
pharmacological treatment, including efficacy, appropri-
ate doses, and adverse effects. Little is known about how
clinicians apply their experience and expert opinion.
This study aimed to report the use of psychotropic drugs
in a specialist setting, including medication doses and
indications; to identify adverse effects; and to describe
characteristics of the patient population including illness
severity and comorbidity and to correlate these with pre-
scribing practices. We also aimed to report monitoring
for medication safety, including ECG monitoring and
QTc prolongation, and metabolic monitoring; and to
document the frequency of significant adverse events
such as deliberate overdose, emergent suicidality while
prescribed SSRIs, and drug-related hyponatraemia. We
hypothesised in general that psychotropic prescription
would be associated with greater patient clinical severity
and complexity, characterised by more severe eating, de-
pressive, anxiety, and dissociative symptomatology, Axis
I comorbidity, onset of deliberate self-harm acts and sui-
cidal ideation, presence of binge eating, and admissions
and bed days. Based on clinical observations, we tenta-
tively hypothesised that there would be an association
between antipsychotic use and emergent binge eating.
Methods
Participants
Participants were patients of Princess Margaret Hospital
for Children (PMH) Eating Disorders Program (EDP).This is the only public specialist child and adolescent
ED service in Western Australia (census population 2
331 500) [37]. The program offers outpatient and day-
patient treatment, and inpatient treatment for medical
stabilisation. The EDP accepts referrals of patients under
age 16 and cares for patients up to gradual transition to
adult services after age 18. At the study enrolment date,
14 April 2011, the EDP had 130 patients. At any given
time, about eight EDP patients are in hospital for med-
ical stabilisation and nutritional rehabilitation.
All ‘active’ patients of PMH EDP (N = 115), who met
Diagnostic and Statistical Manual (DSM-IV) [38] criteria
for an ED at initial assessment, were included. ‘Active’
refers to receiving treatment or follow-up of any kind at
the study enrolment date. From the initial participant
pool of 130, 7 patients were excluded who had not en-
gaged following initial assessment and 8 patients were
excluded as they did not meet criteria for an ED (gener-
ally had subthreshold eating problems).
Service model and provision
All patients are initially assessed through a comprehen-
sive multidisciplinary process, including psychosocial
diagnostic interview; paediatric medical and dietetic as-
sessment; separate interviews of child and parents using
child and parent informant versions of the Eating Dis-
order Examination (EDE) [39]; the Children’s Depression
Inventory (CDI) [40]; the Multidimensional Anxiety
Scale for Children (MASC) [41]; and the Adolescent
Dissociative Experiences Scale (A-DES) [42] self-report
instruments. Information from the assessment is then
reviewed in a multidisciplinary meeting, including the
team psychiatrists, to determine a DSM-IV [38] ED diag-
nosis, any comorbid DSM-IV psychiatric diagnoses, and
treatment plan. Further review by a team psychiatrist is
readily available as needed, for example for diagnostic
clarification, management planning, treatment of comor-
bid psychiatric disorders, and initiation and monitoring
of psychotropic medication where necessary.
Patients are treated in a multidisciplinary team model,
and each patient and family have a care coordinator. All
patients are offered psychological therapy, including indi-
vidual, group, and family therapy in various modalities.
Weight restoration and physical monitoring are prioritised.
Inpatient admissions for malnutrition are under the care of
a paediatric gastroenterology team, with psychological
medicine support, on a paediatric medicine ward, not a
psychiatric ward. The goal of admission is to provide rapid,
intensive nutritional rehabilitation to facilitate prompt re-
turn to family and community, often using nasogastric
tube feeding. On occasion, provided that he or she is not at
acute nutritional risk, a patient is admitted to a separate
acute psychiatric ward for management of comorbid
conditions and self-harm behaviours; close liaison is
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patients.
The prescription of psychotropic medication usually
follows psychiatric assessment by the EDP team con-
sultant psychiatrist, psychiatry registrar or supervised
medical officer. Occasionally, medications are initiated
by paediatric staff. Some patients are referred already
on medication prescribed by their general practitioner
or psychiatrist. Within the EDP, all prescriptions are
through a public hospital pharmacy at the same rela-
tively low cost per medication per month, regardless of
the medication or dosage, and further reduced for con-
cession card holders. Cost to the patient is therefore not
a major influence on prescribing practice.
Measures
Eating disorder examination
Child and parent informant versions of the clinician-
administered structured EDE [39], widely considered the
gold standard for assessing eating disorders, measured se-
verity of eating disorder psychopathology based on the glo-
bal score. Cronbach alpha reliability in the present study
was 0.94.
Children’s depression inventory
The 27-item CDI [40] is a well-established self-report
measure of depressive symptoms with excellent reliabil-
ity and construct validity, and has discriminant validity
as demonstrated by evidence of its utility as a screening
measure for depressive disorders [43]. Cronbach alpha
reliability was 0.91.
Multidimensional anxiety scale for children
Anxiety symptoms were assessed with the self-report 39-
item MASC, which has excellent psychometric proper-
ties [41]. Cronbach alpha reliability was 0.91.
Adolescent dissociative experiences scale
Dissociative symptoms were measured with the self-report
30-item A-DES, which has good reliability and validity,
with increased scores corresponding to lifetime history of
trauma [42]. Cronbach alpha reliability was 0.99.
Other sociodemographic and clinical features
These were extracted from psychological and medical
records or an available clinical audit database. Children
had been weighed wearing underwear and a hospital
gown, using electronic scales accurate to 50 g. Height
had been measured with the patient standing without
shoes and socks, standing on a hard surface and using
a Harpenden stadiometer, accurate to 1 mm. BMI z-
scores had been calculated via Epi Info 7 [44] by
entering the patient’s age, height, and weight into the
program. Z-scores were age- and sex-specific based onthe Centers for Disease Control and Prevention [45,46]
growth charts.
Procedure
The study received approval from the PMH Human Re-
search Ethics Committee as a quality of care audit. A
purpose designed paper form was used to collect infor-
mation retrospectively from the medical file and psychi-
atric file of each patient, by reading through all case
notes, correspondence, assessment materials, and medi-
cation charts. To test the clarity and ease of use of the
form and to evaluate the inter-rater agreement for
extracted data, JKM and EH both collected data from
the same five randomly selected files; no discrepancies
were found, yielding very high inter-rater reliability. Data
collected included age, gender, date of assessment, dur-
ation of illness before referral, inpatient admissions,
medical conditions, body mass index z score, history of
self-harm or suicidal ideation or acts, binge eating his-
tory, EDE, CDI, MASC and A-DES scores; all of these
are consistently and routinely recorded in a standardised
assessment document for each new patient assessed by
EDP. Further data collected included ECG, blood lipids,
fasting blood glucose, and any extrapyramidal symp-
toms, hyponatraemia or QTc prolongation; these were
documented for some patients but not for others. Infor-
mation collected about medication included prescriber,
dose range, and total days of exposure, all of which were
clearly documented for each patient; and indication, ad-
verse effects, and reason for cessation, which were docu-
mented with a variable level of detail. Drug prescriptions
by any prescriber within or external to the EDP were
recorded, both prior to intake assessment at EDP, and
subsequent to assessment, up until the date of the audit.
PRN (pro re nata or “as required”) medication for inpa-
tients was not recorded. A hospital pharmacy database
of all outpatient prescriptions was used to cross-check,
but no missed medications were found.
Data were anonymised at collection with a study ID.
The data collection team included a psychiatrist, advanced
trainee in psychiatry, clinical psychologist, research psych-
ologist, and mental health nurses, who all met to discuss
standardisation of the data collection procedure. JKM (an
advanced trainee in psychiatry) designed the coding pro-
cedure, performed all coding and entered all data into a
spreadsheet. All data were re-checked against the original
paper forms by JKM.
Statistical analysis
A series of analyses of variance (ANOVAs) for continu-
ous outcomes and chi square tests of independence for
categorical outcomes compared those prescribed (pre-
referral and within EDP) versus not prescribed antide-
pressants, antipsychotics, and anxiolytics, respectively on
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take, and during service engagement. The ‘other’ psycho-
tropic category was excluded from comparisons because
of low frequency of use. The relationship between number
of prescriptions and clinical characteristics was examined
by way of ANOVAs and chi square testing. A logistic re-
gression tested whether new binge onset (0 = no, 1 = yes)
could be predicted from antipsychotic medication status
(0 = no/prescribed antipsychotic after date of new binge
onset, 1 = yes). All analyses were preliminary and explora-
tory, hence univariate analysis with no adjustment for
multiple comparisons was used. Alpha was set at the con-
ventional level of .05.
Results
Demographic characteristics
The sample included 115 patients, age 7 to 16 years, with
11 males and 104 females (90% female). The mean age at
referral was 13 years (SD = 1.60). Average duration of en-
gagement from referral up to the point of audit was 2 years
(SD = 1.52 years; range = 25 days to 7 yrs 1 month).
Clinical characteristics
At intake, most met criteria for AN (n = 55, 48%;
restricting subtype, n = 48, 42%; binge-purge subtype, n
= 7, 6%) or EDNOS (n = 54, 47%), and a minority had
BN (n = 6, 5%; purging subtype, n = 4, 3%; non-purging
subtype, n = 2, 2%). The mean age of onset was 12 years
(SD = 1.66) and the mean untreated duration of illness
was 9 months (SD = 7.73). Forty-eight percent (n = 55)
had a comorbid psychiatric diagnosis, most commonly
an anxiety disorder (27%, n = 31) or major depressive epi-
sode (26%, n = 30). Two or more comorbid psychiatric
diagnoses were present in 17% (n = 20). Twenty-seven per-
cent (n = 31) had a comorbid medical diagnosis, the most
frequent being asthma/atopic syndromes.
Psychometric assessments at intake showed above
average depressive and anxiety symptoms, indicated by
mean t scores of 56 (SD = 21.12, n = 109) on the CDI
and 54 (SD = 13.22, n = 108) on the MASC. Using avail-
able data, the proportion with a t score ≥ 65 indicating
clinically significant levels was 37% on the CDI and 24%
on the MASC. Lifetime suicidal ideation was reported
by 28% of cases (present, n = 32; absent, n = 74, 64%; un-
known, n = 9, 8%). Lifetime deliberate self-harm was also
common (present, n = 18, 16%; absent, n = 88, 77%; un-
known, n = 9, 8%). Three cases reported a previous sui-
cide attempt. During engagement with the ED service, a
further 8% (n = 8) had new onset suicidal ideation or in-
tent, 5% (n = 6) had new onset suicide attempts, and
16% (n = 19) had new onset deliberate self-harm. Sixty-
five individuals (57%) had received inpatient treatment.
The median number of admissions for the full sample of
115 patients was one (range 0 to 41) and median totalbed days throughout service engagement was 15 (range
0 to 921).
Drug prescriptions
Psychotropic medication was prescribed to 52 of 115 pa-
tients (45%) pre-assessment or during engagement with
PMH EDP. The youngest age at prescription was
10 years. Prescriptions were relatively infrequent for pre-
adolescents compared to adolescents. The proportion of
patients who were prescribed a psychotropic, by diagno-
sis, was 31/55 (56%) for AN, 4/6 (67%) for BN, and 17/
54 (31%) for EDNOS.
Prescription frequencies prior to specialist service referral
Prior to referral, 9 cases (8%) were prescribed psycho-
tropic medication. There were nine prescriptions, eight
for antidepressants and one for lithium.
Prescription frequencies within the specialist eating disorder
service
Forty-eight of the 115 patients (42%) were prescribed a
new psychotropic medication during treatment within
EDP. There were 138 prescriptions as some cases were
prescribed multiple medications concurrently and/or se-
quentially. During engagement with EDP, 42 (37%) were
prescribed antidepressants, 33 (29%) were prescribed an-
xiolytics or sedative/hypnotics, 25 (22%) were prescribed
antipsychotics, and two (2%) were prescribed other psy-
chotropic medications. Prescriptions were for 21 different
psychotropics. The median time between assessment and
prescription of psychotropic medication was 167 days
(range 3 to 2012 days).
Medication classes
Antidepressants were the most common class prescribed
either pre-referral or within the ED service. Overall (pre-
referral and within EDP), antidepressants were prescribed
in 47 of 115 patients (41%), followed by anxiolytics in 33
(29%), antipsychotics in 25 (22%), and other psychotropics
in three (3%). The main indication for antidepressants was
depression (Table 1).
Antidepressants
Fluoxetine was the most frequently prescribed antidepres-
sant (see Table 1 for indication and dosage characteristics),
comprising 39/60 (65%) of antidepressant prescriptions.
Adverse effects were reported for 9/39 (23%) prescriptions.
Although most were minor (sedation, dizziness, tremor),
there was one case of new onset deliberate self-harm, two
cases of small intentional overdose, and one case of large
intentional overdose. (Here, and in all instances that follow,
“small intentional overdose” is used when the admitting
emergency department doctor described the overdose as
“small” and no treatment or monitoring was required;

































- 1 - - - - - - - - 1 - - -
Citalopram
(32 mg, 20-60 mg)
- 6 3 2 - - - 1 - - - - - -
Desvenlafaxine
(83 mg, 50-100 mg)
- 3 3 - - - - - - - - - - -
Escitalopram
(15 mg, 10-20 mg)
1 1 - 1 - 1 - - - - - - - -
Fluoxetine
(32 mg, 10-60 mg)
4 35 21 4 3 2 2 1 2 2 - 1 1 -
Fluvoxamine
(150 mg, NA)
1 - - - 1 - - - - - - - - -
Mirtazapine
(22 mg, 15-30 mg)
1 1 - - - - - - - - 1 - - 1
Moclobemide
(150 mg, NA)
- 1 1 - - - - - - - - - - -
Sertraline
(100 mg, NA)
1 - 1 - - - - - - - - - - -
Venlafaxine
(168 mg, 150-225 mg)
- 4 2 1 1 - - - - - - - - -
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doctor described the overdose as “large” or inpatient med-
ical treatment, cardiac or respiratory monitoring, pharma-
cological antidote, or intensive care was given). Fluoxetine
was ceased in 15 instances, due primarily to either ineffect-
iveness or patient disengagement.
Twenty-one of 60 (35%) antidepressant prescriptions
were for medications other than fluoxetine (see Table 1).
Many prescriptions (38%, 8/21) occurred after a trial of flu-
oxetine. Five patients prescribed other antidepressant medi-
cations had adverse effects. A patient prescribed citalopram
took a large overdose, while serotonin syndrome and new
onset of suicidality and deliberate self-harm were noted in a
patient prescribed moclobemide. One of the two patients
prescribed mirtazapine developed new onset binge eating.
Dizziness was reported with one patient prescribed sertra-
line. Medication was ceased in 8/21 instances (38%).
There was one case of hyponatraemia (plasma sodium
115 mmol/L) associated with fluoxetine treatment in an
underweight 16 year-old male who had excessive water
consumption; plasma sodium normalised with normalisa-
tion of water intake, while fluoxetine treatment continued.
Antipsychotics
The main indications for antipsychotic medications were
agitation and anxiety (Table 2). All prescriptions were made
during EDP treatment. There were 32 prescriptions for an-
tipsychotics, 24/32 for quetiapine, 7/32 for olanzapine, and
1/32 for risperidone. Adverse events were reported in 41%
(13/32) of prescription instances. Among these were nine
cases prescribed quetiapine; one took a large overdose,
there was clinical concern about precipitation or exacerba-
tion of binge eating in two cases, one had extrapyramidal
side effects while taking quetiapine 75 mg in combination
with fluoxetine 20 mg and lorazepam 3 mg, one had QTc
prolongation, three reported somnolence, and one reported
nightmares. In four cases there was clinical concern that
olanzapine may have precipitated or exacerbated binge eat-
ing. Antipsychotic medication was ceased in 69% (22/32) of
instances.
Anxiolytics and sedative-hypnotics
These were prescribed primarily for insomnia, anxiety,
and agitation (Table 3). Lorazepam comprised more than
half (28/46) of these prescriptions. Adverse effects were
experienced by 13% (6/46) of those prescribed anxio-
lytics, all of whom were taking lorazepam. One adoles-
cent took a small overdose, four reported somnolence,
and one reported nausea. Medication was ceased in 83%
of prescription instances (38/46).
Other medications
One patient was prescribed lithium pre-referral for a
diagnosis of bipolar disorder. Lithium was ceased afterEDP assessment with revision of the diagnosis. During EDP
engagement, one patient was prescribed St John’s wort by
an external clinician for depression, and one was prescribed
atomoxetine then dexamphetamine for attention deficit-
hyperactivity disorder.
Pharmacotherapy vs. non-pharmacotherapy patient
characteristics
Exploratory ANOVAs and chi square tests comparing
those prescribed and not prescribed antidepressants on
the clinical variables in Table 4 (results not presented),
showed that the group prescribed antidepressant medica-
tion had significantly higher EDE, CDI, A-DES, Axis I co-
morbidity, binge eating presence, admissions, bed days,
new onset deliberate self-harm and suicidality, and were
less likely to have EDNOS (ps < .05). The group prescribed
antipsychotic medication had significantly higher EDE,
CDI, Axis I comorbidity, admissions, bed days, binge eat-
ing presence, and new onset deliberate self-harm and
suicidality. Compared to those who did not receive anxio-
lytics, the group prescribed anxiolytics had higher EDE,
CDI, Axis I comorbidity, admissions, bed days, binge eat-
ing presence, and new onset deliberate self-harm and
suicidality, and were less likely to have EDNOS (ps < .05).
Number of prescriptions and polypharmacy
The total number of drugs prescribed per patient within
PMH EDP ranged from 0 to 7. ANOVA and chi square
analyses showed that of the clinical variables presented in
Table 4, a higher number of prescriptions was associated
with clinical severity (characterised by more severe eating
and depressive symptomatology, Axis I comorbidity, onset
of deliberate self-harm acts and suicidal ideation, presence
of binge eating, and more admissions and bed days).
Concurrent prescriptions (i.e., having more than one
prescription at a time) occurred during service engage-
ment in 30% (34/115) of patients. The maximum number
of concurrent prescriptions was four, with the following
proportions: two drugs for 17% (19/115), three drugs for
10% (12/115), and four drugs for 3% (3/115). An anti-
depressant combined with an anxiolytic, an antipsychotic,
or both, were the most common combinations.
Medication safety
Safety considerations studied included QTc prolongation,
ECG monitoring and metabolic monitoring for SGAs, de-
liberate overdose, and emergent suicidality with SSRIs.
Another objective was to investigate the possibility of
emergent binge eating with antipsychotics.
QTc prolongation on ECG of clinical concern was
recorded in two patients; both were nutritionally com-
promised, dehydrated female adolescent inpatients. The
QTc prolongation did not result in adverse clinical con-
sequences. One patient was prescribed olanzapine,




























(6.8 mg, 2.5-15 mg)
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Quetiapine
(56 mg, 12.5-200 mg)
- 24 7 4 3 2 1 1 1 1 1 1 1 1
Risperidone
(1 mg, NA)
- 1 - 1 - - - - - - - - - -

































Clonazepam (2.3 mg, 1–4 mg) - 4 - - 2 1 1 - - -
Lorazepam (1.7 mg, 0.5-4 mg) - 28 2 12 4 4 2 1 1 2
Melatonin (1.9 mg, 1.5-2 mg) - 5 5 - - - - - - -
Nitrazepam (15 mg, 10–20 mg) - 2 2 - - - - - - -
Temazepam (10 mg, 5–20 mg) - 7 6 - - - - - - 1
Total 46 15 (33%) 12 (26%) 6 (13%) 5 (11%) 3 (7%) 1 (2%) 1 (2%) 3 (7%)
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http://www.jeatdisord.com/content/1/1/27clonazepam, nitrazepam and omeprazole, and had normal
electrolytes. Medications were continued, and the mild
QTc prolongation of 469 ms resolved over three weeks as
her nutritional state improved. The other was prescribed
fluoxetine and recently commenced quetiapine, and had
hypophosphataemia. Quetiapine was ceased, she wasTable 4 Pre-referral, intake, and during service engagement c
three or more psychotropic medications within a specialist ch
Nu
Time Characteristic 0 (n = 66)
Pre-referral Age at onset, yrs 12.79 (1.79)
Untreated duration of illness, mths 8.64 (7.61)
History of DSH/suicidal ideation 27% (16)
History of DSH acts 15% (9)
History of suicidal acts 3% (2)






Axis I comorbidity 29% (19)
EDE 2.53 (1.57)
CDI t score 51.60 (21.87)
MASC t score 52.94 (13.47)
ADES 1.95 (1.71)
BMI z score −1.50 (1.38)
EDP Inpatient admissions 0.48 (.71)
Inpatient bed days 11.67 (18.59)
DSH new onset 2% (1)
Suicidality new onset 3% (2)
Presence of objective binge episodes 24% (16)
Data are presented as means (standard deviations) or percentages (number) and are b
post hoc analyses indicate whether cell counts are lower or higher than would be expe
Experiences Scale; AN = anorexia nervosa; BN = bulimia nervosa; BMI = body mass ind
deliberate self-harm; EDE = Eating Disorder Examination; EDNOS = eating disorders no
MASC = Multidimensional Anxiety Scale for Children. Missing data for some individuals
onset, n = 110.rehydrated and electrolytes were normalised, and the QTc
prolongation of 500 ms resolved within 24 hours.
Quetiapine was never reintroduced.
Only four of the 25 patients treated with a SGA had
an ECG at baseline, and two had a repeat ECG within
2 weeks of initiation.haracteristics of those prescribed none, one to two, or
ild and adolescent eating disorders program.
mber of prescriptions
1-2 (n = 27) 3+ (n = 22) p post hoc
12.81 (1.64) 12.95 (1.29) ns -
11.11 (7.98) 8.89 (7.76) ns -
33% (8) 36% (8) ns -
21% (5) 22% (4) ns -
0% (0) 5% (1) ns -
13.85 (1.49) 13.73 (1.60) ns -
ns -
48% (13) 68% (15) - -
52% (14) 32% (7) - -
7% (2) 9% (2) - -
44% (12) 23% (5) - -
74% (20) 73% (16) <.001 0 < exp; 1–2 > exp
2.94 (1.59) 3.88 (1.58) .003 1-2, 3+ > 0
59.77 (17.80) 67.045 (18.33) .008 3+ > 0
53.24 (11.66) 59.10 (13.22) ns -
2.16 (1.80) 2.57 (2.17) ns -
−1.60 (1.20) −1.76 (.96) ns -
2.04 (2.28) 6.82 (8.82) <.001 3+ > 0, 1-2
59.96 (82.69) 166.05 (218.58) <.001 3+ > 0, 1-2
20% (5) 59% (13) <.001 0 < exp; 3+ > exp
15% (4) 36% (8) <.001 0 < exp; 3+ > exp
38% (10) 68% (15) .001 3+ > exp
ased on available data only (i.e., missing or unknown data excluded). Chi square
cted based on equivalent count distributions. ADES = Adolescent Dissociative
ex; CDI = Children’s Depression Inventory; DOI = duration of illness; DSH =
t otherwise specified; EDP = eating disorders program; exp = expected cell count;
; available data: EDE n = 111, CDI n = 109, MASC n = 108, ADES n = 91, DSH new
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http://www.jeatdisord.com/content/1/1/27Self-harm by overdose was observed in 11% (6/52) of
patients prescribed a psychotropic drug, with one taking
an overdose on two separate occasions. Although there
were no permanent sequelae, three instances involved
large, potentially dangerous dosages.
In patients prescribed SGAs, none had monitoring of
blood glucose or lipids at any time.
There were no completed suicides in the cohort (or in
previous active cases since program inception). Of 106
evaluable patients, 3/42 (7%) prescribed antidepressants
with an FDA black box warning label of suicidal risk (fluox-
etine, sertraline, paroxetine, citalopram, escitalopram, flu-
voxamine) experienced suicidality onset within 3 months of
initiation, and overall 14/106 (13%) had suicidality onset at
some time.
Eighty-three percent (96/115) of patients were binge ab-
stinent at intake, and 19% (22/115) of the entire sample
developed new binge eating during treatment in the EDP.
An exploratory logistic regression showed that medication
status reliably distinguished between those with and with-
out new binge onset, χ2(1) = 3.93, p = .047. The odds ratio
of new binge onset was 3.5 times as large for a patient pre-
scribed antipsychotic medication than the odds for a pa-
tient not prescribed antipsychotic medication. Of the six
patients with new binge onset after SGA initiation, three
were prescribed olanzapine and three quetiapine. The ex-
posure time before recorded binge onset ranged from 7 to
667 days (M = 260 days exposure, SD = 235 days).Discussion
To the best of our knowledge, this is the first retrospective
case note study of psychotropic drug prescribing in an
Australian specialist child and adolescent ED program.
Forty-five percent of patients were prescribed psychotropic
medication. In our sample, 48% had one or more comorbid
Axis I psychiatric diagnoses, consistent with reported high
comorbidity [47,48]. Those with psychiatric comorbidity
were significantly more likely to be prescribed medication.
There was a significant relationship between prescribing
(including number of prescriptions) and disease severity
and number and total length of hospital admissions. Ad-
verse effects of medication were commonly recorded and
somewhat higher for antipsychotic medications (39%) than
antidepressants (23%). Most of these adverse effects were
minor, although there were a number of instances of non-
fatal self-harm by overdose of medication. Deliberate over-
dose of prescribed medication was relatively frequent. The
study showed a very preliminary association between emer-
gent binge eating and antipsychotic use in this population,
which may be explained by mechanisms linking SGAs and
appetite dysregulation [49]. Before being accepted, this
finding needs replication to establish that it is not reflective
of sampling variability or a Type I error.The prevalence of psychotropic prescription in this
study was higher than reported by Gowers et al. [36] or
Rossi et al. [35]. It is difficult to compare services operat-
ing in different countries, which probably have different
patient populations, service resources, and care philoso-
phies. In our sample 57% received inpatient treatment at
some time compared with 41% in Gowers et al. [36].
These figures are not directly comparable, as different ser-
vices have different criteria for admission, but may suggest
a more severely unwell population in our study. Gowers
et al. also reported a prevalence of 23% for comorbid psy-
chiatric disorders, less than half the prevalence for our
sample. The study designs differed, for example, Gowers
et al. reported on prescribing during a 12-month period
for all subjects, whereas we reported prescribing during
the full period of engagement with the EDP, which aver-
aged 24 months.
The medication dosages used were low to medium for
antipsychotics. For antidepressants, most dosages were
low to medium, but a few patients were on higher doses
of selective serotonin uptake inhibitors, in line with
usual clinical practice for adults with bulimia nervosa.
No conclusions can be drawn about effectiveness or
safety of dosages from the data.
Patients within our service were prescribed more benzo-
diazepines, such as lorazepam, than reported by Gowers
et al. [36]: 29% of total prescriptions were for benzodiaze-
pines, often for a short period. There were no cases of
benzodiazepine abuse or other serious adverse effects. Se-
vere and persistent insomnia was a common, distressing
symptom in our patient population. Insomnia was noted
as a consequence of malnutrition in a classic starvation
experiment [50], though clinical literature on insomnia in
EDs is lacking. We speculate that the rate of benzodiazep-
ine prescription may reflect the clinical difficulties of man-
aging acute re-feeding on a busy general paediatric ward
without specialist mental health nursing and with limited
resources to provide structured support for EDP patients:
anxiety, agitation, and insomnia are common complaints
in this setting.
Patients with EDs constitute a highly distressed, high-
risk population, with prevalent suicidal attempts and
ideation and deliberate self-harm. Among adults, 3% to
20% with AN and 25% to 35% with BN report a history
of attempted suicide; completed suicide is more com-
mon in AN than BN [15,16]. Exact rates among children
and adolescents are unknown. In our study, 11% of pa-
tients prescribed medication (6/52 patients) self-harmed
by overdose on their prescribed psychotropic medica-
tion. Attention to prescribing medications of lower risk
in overdose, limiting amount dispensed, observing medi-
cation being swallowed to reduce potential for hoarding,
and engaging patients and families in maintaining safe
medication storage are commonsense measures.
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increases with SSRIs in a paediatric ED population; how-
ever, given there is a heightened risk in youth with anx-
iety and depressive problems to age 25 years, and that
anxiety and depressive comorbidity is common in ED
populations, this is an important safety concern. Of 20
patients who developed suicidality during service en-
gagement, three of the 18 evaluable who had onset date
recorded were within three months of SSRI initiation.
Routine clinical monitoring for suicidality in ED popula-
tions is imperative, and future investigation of suicidality
risk with SSRIs in paediatric ED patients is warranted.
Routine monitoring of metabolic parameters in patients
prescribed antipsychotic medications is recommended by
Australian guidelines [51]. Hyperlipidaemia is a common
complication of antipsychotic therapy even in underweight
young patients with EDs [19]. The PMH protocol for
SGAs specifies regular monitoring of metabolic parame-
ters; monitoring of weight and blood pressure is universalTable 5 Proposal for prescribing psychotropic medication for
Principle Key elements
1. Adjunctive treatment in
selected patients
a. In context of comprehensive medical and
b. For relief of persistent distressing sympto
c. For treatment of comorbid psychiatric dis
2. Informed consent a. Patient and family/carers
b. Discuss rationale, potential benefits, poten
c. Choice of medication informed by individ
d. Documentation
3. Record baseline information a. Identify target symptoms
b. Document level of baseline symptoms an
c. Use appropriate pre and post rating scale
d. Screen for suicidality and binge eating
e. Baseline investigations e.g. electrolytes, EC
4. Treat a. Start at low doses, increase cautiously
b. Safe prescription and storage to reduce h
c. Enlist patient and family in adherence and
5. Monitor a. Monitor treatment response clinically and
b. Monitor for adverse effects
1. Screen for binge eating and suicidality
2. Examination for extrapyramidal adverse ef
3. Monitor for SGAs with ECG, serum lipids,
6. Review a. Regular review of balance of benefit and
b. Continue if effective and tolerated, cease
c. Minimise polypharmacy
d. Maintain emphasis on non-pharmacologi
e. Review appropriateness as patient’s nutrit
7. Audit a. Collect and share data on prescription, eff
b. Implement service-wide procedures that fadue to the close medical monitoring of EDP patients, but
clinician compliance with monitoring of blood lipids and
glucose was lacking. Compliance with ECG monitoring
for QTc prolongation in patients prescribed SGAs was
low. This problem of translating evidence-based guidelines
into routine clinical care is not unique to our service; low
compliance with metabolic monitoring has been reported
internationally [52]. An Australian specialist youth service
has recently reported on barriers and enabling factors for
metabolic monitoring within a first episode psychosis
clinic [52] and showed substantial improvement in screen-
ing and monitoring after a package of interventions [53].
Limitations of this study include a retrospective audit
design; adverse effects of medication may be under-
recorded when pharmacovigilance occurs via spontaneous
reporting [54]. This is likely to be particularly true for
binge eating, which tends to be concealed. The retrospect-
ive design led to limitations due to variability in documen-
tation; for example, if a prescriber documented “anxiety”children and adolescents with eating disorders.
psychological assessment and treatment, including weight restoration
ms
orders




G, fasting lipids and fasting blood sugar prior to prescribing SGAs
arm from intentional overdose
monitoring
using appropriate rating scales
fects of SGAs
fasting blood sugar, weight, any other measures specific to the drug
risk
if ineffective or poorly tolerated
cal treatments
ional state changes
ectiveness and adverse effects
cilitate good prescribing and monitoring practices and allow data collection
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whether the patient met criteria for a particular DSM-IV
anxiety disorder at that time. Comorbid Axis I diagnoses
were assigned clinically without the administration of gold
standard structured interviews, which reduces reliability.
We classified deliberate overdose of prescription medica-
tion as an adverse effect related to that medication; this
methodology may differ from that used by other authors.
No conclusions can be drawn about efficacy of psycho-
tropic medications in managing EDs. Our results may dif-
fer from the prescription of medication in other ED
treatment settings. In particular, because all medications
were supplied at standard PBS charges, these findings may
not generalise to other settings in which high cost to the
patient may limit off-label use of antipsychotic medica-
tions. Analyses are preliminary and exploratory, with
many variables, and occurred in the context of an observa-
tional design with a sample size pre-determined by the
“active” caseload; in future replications due attention will
need to be given to statistical power and controlling the
Type 1 error rate. Chi-square analyses must be interpreted
tentatively as sometimes data were unevenly distributed
across cells, leading to violations in expected cell counts.
Nonetheless, the presented results correlating prescribing
practices to severity and complexity of presentation have
clinical validity. Adherence to prescribed medication could
not be formally evaluated due to the retrospective audit
design; therefore, safety and risk data may underestimate
actual risk. We enrolled only patients who were “active”,
that is, receiving some form of treatment or follow up at
the study commencement date. To maximise current clin-
ical relevance, we chose to study only the current group,
as prescribing practices and medications available have
changed over the 10 years since the EDP’s inception; how-
ever, this led to a potential source of bias by excluding pa-
tients who had dropped out of treatment, who may have
different characteristics.
Conclusions
Our hope is that this study will provide a template for fu-
ture studies, which may include the follow up of this co-
hort, as well as multicentre collaboration examining the
efficacy and utility of psychotropic medication in managing
paediatric EDs, with larger samples and a prospective de-
sign. Given the difficulty of conducting large randomised
controlled trials of medication in this patient population
[55], reports of actual prescribing practices, medication
safety, and treatment outcomes in a naturalistic setting are
of value. Understanding the prevalence and indications of
psychotropic use is essential to considering their place in
clinical practice and implications for service provision, in-
cluding treatment and safety monitoring. We propose
some principles to guide prescription of psychotropics for
children and adolescents with eating disorders (Table 5).Abbreviations
A-DES: Adolescent dissociative experiences scale; AN: Anorexia nervosa;
ANOVAs: Analyses of variance; BN: Bulimia nervosa; CDI: Children’s depression
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EDE: Eating disorder examination; EDs: Eating disorders; EDNOS: EDs not
otherwise specified; EDP: Eating disorders program; MASC: Multidimensional
anxiety scale for children; OCD: Obsessive-compulsive disorder; PMH: Princess
margaret hospital for children; PRN: Pro re nata or “as required”;
SGAs: Second generation antipsychotics; SSRIs: Selective serotonin reuptake
inhibitors..
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